BioMarin Pharmaceutical Company Profile (NASDAQ:BMRN)

About BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical logoBioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:BMRN
  • CUSIP: 09061G10
  • Web: www.bmrn.com
Capitalization:
  • Market Cap: $16.3946 billion
  • Outstanding Shares: 175,268,000
Average Prices:
  • 50 Day Moving Avg: $92.56
  • 200 Day Moving Avg: $90.07
  • 52 Week Range: $78.42 - $100.51
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -246.17
  • P/E Growth: -5.28
Sales & Book Value:
  • Annual Revenue: $1.2 billion
  • Price / Sales: 12.94
  • Book Value: $15.95 per share
  • Price / Book: 5.56
Profitability:
  • EBITDA: ($106,700,000.00)
  • Net Margins: -15.54%
  • Return on Equity: -5.77%
  • Return on Assets: -4.00%
Debt:
  • Debt-to-Equity Ratio: 0.24%
  • Current Ratio: 3.90%
  • Quick Ratio: 2.75%
Misc:
  • Average Volume: 1.31 million shs.
  • Beta: 1.85
  • Short Ratio: 5.6
 

Frequently Asked Questions for BioMarin Pharmaceutical (NASDAQ:BMRN)

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its earnings results on Wednesday, August, 2nd. The company reported ($0.21) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.22) by $0.01. The company earned $317.50 million during the quarter, compared to analysts' expectations of $311.41 million. BioMarin Pharmaceutical had a negative return on equity of 5.77% and a negative net margin of 15.54%. The business's revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the business posted ($2.61) EPS. View BioMarin Pharmaceutical's Earnings History.

When will BioMarin Pharmaceutical make its next earnings announcement?

BioMarin Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for BioMarin Pharmaceutical.

Where is BioMarin Pharmaceutical's stock going? Where will BioMarin Pharmaceutical's stock price be in 2017?

22 analysts have issued 1-year price objectives for BioMarin Pharmaceutical's shares. Their forecasts range from $89.00 to $150.00. On average, they expect BioMarin Pharmaceutical's share price to reach $113.10 in the next year. View Analyst Ratings for BioMarin Pharmaceutical.

What are analysts saying about BioMarin Pharmaceutical stock?

Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock:

  • 1. According to Zacks Investment Research, "BioMarin should continue to see growth in both its orphan disease drugs – Vimizim and Kuvan – in 2017 backed by robust patient growth and penetration. Pipeline development is also on track with a potential approval for pegvaliase in 2018. However, BioMarin has suffered quite a few regulatory setbacks related to its pipeline candidates, Brineura and Kyndrisa. Delayed approvals or development setbacks could have a negative impact on the stock. Also, Naglazyme revenues vary on a quarterly basis primarily due to infrequent ordering patterns from some countries. Meanwhile, BioMarin is facing generic threat for Kuvan. The earlier-than-expected entry of generics will be a huge blow for the company.  The stock has underperformed the industry in the past six months. Loss estimates have slightly widened ahead of the company’s Q3 earnings result. BioMarin has a positive record of earnings surprises in the recent quarters." (10/16/2017)
  • 2. Cowen and Company analysts commented, "New data include 52 wk follow-up on all patients at BMN270’s 6e13 vg/kg dose, and." (7/11/2017)
  • 3. Wedbush analysts commented, "The Wedbush View: While we see meaningful clinical, regulatory and commercial progress this year, we remain NEUTRAL on BMRN as we believe the stock is relatively expensive as it consistently trades at the top of peers." (5/8/2017)
  • 4. Jefferies Group LLC analysts commented, "Narrower 1Q GAAP net loss reflects higher revenue & lower OpEx (non- GAAP income of $35M). Next clinical update includes BMN 270 data at ISTH on 7/8-7/13/17." (5/5/2017)
  • 5. J P Morgan Chase & Co analysts commented, "By Lotus Inventory Impacting Margins In Q1, all rev lines came in above expectations. While Med-Surg has been a consistent outperformer of late, CRM upside was another bright spot. The strong growth came against a tough comp. Headline margins were disappointing due to a spate of issues including the Lotus recall (not surprising), Fuse scope losses (somewhat more surprising) and litigation charges (also not surprising). The Lotus and Fuse charges are not expected to recur; excluding these, we view margins as fairly in-line. While the revenue raise positions BSX shares more favorably in our view, we continue to see the potential for risk around Lotus. While we expect strong data at EuroPCR, we wonder if mgmt’s FDA timelines are aggressive as we would think the FDA might ask for meaningful additional clinical work on the new delivery system following the EU recall. We remain positive on BSX’s underlying fundamentals but feel its current P/E valuation is appropriate until Lotus issues are entirely resolved or Symetis closes and sales ramp." (5/1/2017)

Who are some of BioMarin Pharmaceutical's key competitors?

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the folowing people:

  • Jean-Jacques Bienaime, Chairman of the Board, Chief Executive Officer
  • Daniel Keith Spiegelman, Chief Financial Officer, Executive Vice President
  • G. Eric Davis, Executive Vice President, General Counsel, Secretary
  • Jeff Robert Ajer, Executive Vice President, Chief Commercial Officer
  • Robert A. Baffi Ph.D., Executive Vice President - Technical Operations
  • Henry J. Fuchs M.D., Executive Vice President and Chief Medical Officer
  • Brian R. Mueller, Group Vice President, Corporate Controller, Chief Accounting Officer
  • Richard A. Meier, Lead Independent Director
  • Willard H. Dere M.D., Independent Director
  • Michael G. Grey, Independent Director

Who owns BioMarin Pharmaceutical stock?

BioMarin Pharmaceutical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Eqis Capital Management Inc. (0.01%). Company insiders that own BioMarin Pharmaceutical stock include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, Robert Baffi and V Bryan Lawlis. View Institutional Ownership Trends for BioMarin Pharmaceutical.

Who sold BioMarin Pharmaceutical stock? Who is selling BioMarin Pharmaceutical stock?

BioMarin Pharmaceutical's stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. Company insiders that have sold BioMarin Pharmaceutical stock in the last year include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Robert Baffi and V Bryan Lawlis. View Insider Buying and Selling for BioMarin Pharmaceutical.

How do I buy BioMarin Pharmaceutical stock?

Shares of BioMarin Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioMarin Pharmaceutical's stock price today?

One share of BioMarin Pharmaceutical stock can currently be purchased for approximately $88.62.


MarketBeat Community Rating for BioMarin Pharmaceutical (NASDAQ BMRN)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  870 (Vote Outperform)
Underperform Votes:  404 (Vote Underperform)
Total Votes:  1,274
MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BioMarin Pharmaceutical (NASDAQ:BMRN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Hold Ratings, 16 Buy Ratings
Consensus Rating:Buy (Score: 2.73)
Consensus Price Target: $113.10 (27.62% upside)
Consensus Price Target History for BioMarin Pharmaceutical (NASDAQ:BMRN)
Price Target History for BioMarin Pharmaceutical (NASDAQ:BMRN)
Analysts' Ratings History for BioMarin Pharmaceutical (NASDAQ:BMRN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/19/2017Leerink SwannReiterated RatingOutperform$136.00 -> $142.00N/AView Rating Details
10/19/2017Credit Suisse GroupReiterated RatingOutperform$114.00 -> $124.00N/AView Rating Details
10/6/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy -> Buy$129.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingOverweight$115.00 -> $117.00N/AView Rating Details
9/26/2017Jefferies Group LLCReiterated RatingBuy$116.00LowView Rating Details
9/21/2017Piper Jaffray CompaniesReiterated RatingBuy$113.00MediumView Rating Details
9/15/2017BMO Capital MarketsReiterated RatingBuyLowView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageSector Perform -> Sector Perform$93.00MediumView Rating Details
8/31/2017Citigroup Inc.Initiated CoverageBuy -> Buy$98.00MediumView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$100.00HighView Rating Details
8/9/2017Deutsche Bank AGReiterated RatingBuy$118.00 -> $119.00LowView Rating Details
8/7/2017WedbushReiterated RatingNeutral$108.00HighView Rating Details
8/4/2017Stifel NicolausReiterated RatingBuy$107.00LowView Rating Details
8/4/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$89.00HighView Rating Details
7/22/2017Barclays PLCReiterated RatingEqual Weight$105.00 -> $100.00LowView Rating Details
7/14/2017SunTrust Banks, Inc.Reiterated RatingBuy$115.00LowView Rating Details
5/1/2017J P Morgan Chase & CoReiterated RatingBuyMediumView Rating Details
3/1/2017InstinetInitiated CoverageNeutral -> Neutral$93.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageNeutralN/AView Rating Details
2/10/2017GabelliReiterated RatingBuyN/AView Rating Details
1/9/2017Robert W. BairdSet Price TargetBuy$115.00N/AView Rating Details
7/28/2016William BlairSet Price TargetBuy$116.00N/AView Rating Details
6/20/2016Oppenheimer Holdings, Inc.Reiterated RatingMarket Perform$99.00N/AView Rating Details
1/15/2016Bank of America CorporationReiterated RatingBuy$165.00 -> $135.00N/AView Rating Details
(Data available from 10/19/2015 forward)

Earnings

Earnings History for BioMarin Pharmaceutical (NASDAQ:BMRN)
Earnings by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)
Earnings History by Quarter for BioMarin Pharmaceutical (NASDAQ BMRN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/26/2017($0.24)N/AView Earnings Details
8/2/2017Q2 2017($0.22)($0.21)$311.41 million$317.50 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.30)$0.03$292.58 million$303.70 millionViewListenView Earnings Details
2/23/2017Q416($0.38)($0.53)$296.54 million$300.00 millionViewN/AView Earnings Details
10/27/2016Q316($0.39)($0.13)$289.70 million$279.90 millionViewListenView Earnings Details
8/4/2016Q216($0.52)($2.61)$278.75 million$300.10 millionViewN/AView Earnings Details
4/28/2016Q116($0.85)($0.53)$240.21 million$236.70 millionViewListenView Earnings Details
2/25/2016Q415$0.67$0.39$224.14 million$227.90 millionViewListenView Earnings Details
10/29/2015Q315($0.65)($0.60)$216.32 million$208.90 millionViewListenView Earnings Details
8/3/2015Q215($0.53)($0.22)$218.16 million$250.50 millionViewN/AView Earnings Details
4/30/2015Q1($0.53)($0.25)$204.58 million$203.26 millionViewN/AView Earnings Details
2/25/2015Q414($0.59)($0.30)$189.01 million$230.90 millionViewN/AView Earnings Details
10/23/2014Q314($0.22)($0.16)$206.00 million$176.80 millionViewListenView Earnings Details
7/30/2014Q214($0.42)($0.19)$159.70 million$191.70 millionViewN/AView Earnings Details
5/1/2014Q1 2014($0.50)($0.27)$145.16 million$151.60 millionViewN/AView Earnings Details
2/26/2014Q413($0.35)($0.11)$146.07 million$146.90 millionViewN/AView Earnings Details
10/24/2013Q313($0.30)($0.38)$140.00 million$136.90 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.29)($0.16)$134.33 million$136.80 millionViewN/AView Earnings Details
4/25/2013Q1 2013($0.30)($0.31)$131.35 million$127.90 millionViewN/AView Earnings Details
2/21/2013Q4 2012($0.22)($0.43)$129.70 million$130.96 millionViewN/AView Earnings Details
10/25/2012($0.20)($0.04)ViewN/AView Earnings Details
8/1/2012($0.19)($0.27)ViewN/AView Earnings Details
4/26/2012($0.15)($0.21)ViewN/AView Earnings Details
2/16/2012($0.10)($0.23)ViewN/AView Earnings Details
10/27/2011($0.10)($0.16)ViewN/AView Earnings Details
7/28/2011($0.09)($0.05)ViewN/AView Earnings Details
4/28/2011($0.10)$0.14ViewN/AView Earnings Details
2/17/2011($0.02)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)
2017 EPS Consensus Estimate: ($0.94)
2018 EPS Consensus Estimate: $0.07
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.38)($0.22)($0.32)
Q2 20174($0.35)($0.17)($0.26)
Q3 20175($0.16)($0.02)($0.08)
Q4 20175($0.40)($0.10)($0.28)
Q1 20181($0.14)($0.14)($0.14)
Q2 20181$0.04$0.04$0.04
Q3 20181$0.06$0.06$0.06
Q4 20181$0.11$0.11$0.11
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BioMarin Pharmaceutical (NASDAQ:BMRN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for BioMarin Pharmaceutical (NASDAQ:BMRN)
Insider Ownership Percentage: 1.85%
Institutional Ownership Percentage: 97.29%
Insider Trades by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)
Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)
Insider Trades by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/28/2017Robert BaffiEVPSell18,415$92.43$1,702,098.45View SEC Filing  
9/22/2017Jeffrey Robert AjerEVPSell3,521$95.00$334,495.00View SEC Filing  
9/15/2017Henry J FuchsInsiderSell15,000$90.50$1,357,500.00View SEC Filing  
9/15/2017V Bryan LawlisDirectorSell3,750$91.26$342,225.00View SEC Filing  
6/23/2017George Eric DavisEVPSell9,844$96.60$950,930.40View SEC Filing  
6/22/2017Brian MuellerSVPSell2,671$100.00$267,100.00View SEC Filing  
6/19/2017Henry J FuchsInsiderSell15,000$90.00$1,350,000.00View SEC Filing  
6/16/2017V Bryan LawlisDirectorSell3,750$90.00$337,500.00View SEC Filing  
6/7/2017Jeffrey Robert AjerEVPSell1,004$89.61$89,968.44View SEC Filing  
6/5/2017George Eric DavisEVPSell9,471$91.04$862,239.84View SEC Filing  
6/5/2017Jean Jacques BienaimeCEOSell10,000$90.13$901,300.00View SEC Filing  
5/24/2017Jean Jacques BienaimeCEOSell5,000$88.38$441,900.00View SEC Filing  
5/17/2017Jean Jacques BienaimeCEOSell5,000$91.73$458,650.00View SEC Filing  
5/8/2017Brian MuellerSVPSell7,482$91.87$687,371.34View SEC Filing  
5/8/2017Jean Jacques BienaimeCEOSell10,000$96.09$960,900.00View SEC Filing  
5/5/2017George Eric DavisEVPSell2,500$100.34$250,850.00View SEC Filing  
5/2/2017Jeffrey Robert AjerEVPSell302$96.74$29,215.48View SEC Filing  
4/27/2017Jean Jacques BienaimeCEOSell5,000$95.72$478,600.00View SEC Filing  
4/25/2017Jean Jacques BienaimeCEOSell5,000$94.00$470,000.00View SEC Filing  
3/29/2017Jeffrey Robert AjerEVPSell3,890$89.15$346,793.50View SEC Filing  
3/16/2017Daniel K SpiegelmanCFOSell1,989$91.96$182,908.44View SEC Filing  
3/16/2017George Eric DavisEVPSell2,238$91.96$205,806.48View SEC Filing  
3/16/2017Jean Jacques BienaimeCEOSell10,000$91.69$916,900.00View SEC Filing  
3/10/2017Jean Jacques BienaimeCEOSell11,000$90.59$996,490.00View SEC Filing  
3/7/2017Jeffrey Robert AjerEVPSell5,000$90.56$452,800.00View SEC Filing  
3/6/2017Daniel K SpiegelmanCFOSell2,303$93.32$214,915.96View SEC Filing  
3/6/2017George Eric DavisEVPSell1,498$93.32$139,793.36View SEC Filing  
3/1/2017Daniel K SpiegelmanCFOSell35,000$94.07$3,292,450.00View SEC Filing  
3/1/2017V Bryan LawlisDirectorSell7,500$95.00$712,500.00View SEC Filing  
2/24/2017Henry J FuchsInsiderSell15,000$87.99$1,319,850.00View SEC Filing  
1/26/2017Jean Jacques BienaimeCEOSell10,000$84.22$842,200.00View SEC Filing  
1/11/2017Jean Jacques BienaimeCEOSell8,000$90.58$724,640.00View SEC Filing  
1/9/2017Daniel K SpiegelmanCFOSell5,000$90.00$450,000.00View SEC Filing  
1/9/2017Jean Jacques BienaimeCEOSell8,000$88.49$707,920.00View SEC Filing  
12/30/2016Jean Jacques BienaimeCEOSell8,000$83.60$668,800.00View SEC Filing  
11/22/2016Jean Jacques BienaimeCEOSell69,743$85.69$5,976,277.67View SEC Filing  
11/21/2016Jean Jacques BienaimeCEOSell69,744$87.56$6,106,784.64View SEC Filing  
11/8/2016Jean Jacques BienaimeCEOSell140,000$82.67$11,573,800.00View SEC Filing  
11/7/2016Jean Jacques BienaimeCEOSell70,000$82.52$5,776,400.00View SEC Filing  
10/28/2016Jean Jacques BienaimeCEOSell120,000$81.30$9,756,000.00View SEC Filing  
10/17/2016Jean Jacques BienaimeCEOSell41,666$84.39$3,516,193.74View SEC Filing  
10/14/2016Jean Jacques BienaimeCEOSell64,125$86.96$5,576,310.00View SEC Filing  
9/29/2016Jean Jacques BienaimeCEOSell53,125$93.65$4,975,156.25View SEC Filing  
9/27/2016Jeffrey Robert AjerEVPSell18,467$95.61$1,765,629.87View SEC Filing  
9/16/2016Jean Jacques BienaimeCEOSell137,368$95.34$13,096,665.12View SEC Filing  
8/26/2016Henry J FuchsEVPSell15,000$95.06$1,425,900.00View SEC Filing  
8/16/2016Jean Jacques BienaimeCEOSell41,666$91.49$3,812,022.34View SEC Filing  
8/1/2016Brian MuellerVPSell287$100.00$28,700.00View SEC Filing  
8/1/2016Daniel K SpiegelmanCFOSell4,000$99.33$397,320.00View SEC Filing  
8/1/2016George Eric DavisEVPSell2,167$100.00$216,700.00View SEC Filing  
7/27/2016V Bryan LawlisDirectorSell1,100$95.39$104,929.00View SEC Filing  
7/22/2016V Bryan LawlisDirectorSell6,400$95.01$608,064.00View SEC Filing  
7/18/2016Jean Jacques BienaimeCEOSell41,666$92.72$3,863,271.52View SEC Filing  
7/7/2016George Eric DavisEVPSell2,167$90.00$195,030.00View SEC Filing  
6/20/2016V Bryan LawlisDirectorSell550$82.77$45,523.50View SEC Filing  
6/16/2016Jean Jacques BienaimeCEOSell41,666$80.55$3,356,196.30View SEC Filing  
6/6/2016Daniel K SpiegelmanCFOSell1,649$89.14$146,991.86View SEC Filing  
5/31/2016Daniel K SpiegelmanCFOSell20,841$89.88$1,873,189.08View SEC Filing  
5/26/2016Henry J FuchsEVPSell15,000$87.81$1,317,150.00View SEC Filing  
5/23/2016Daniel K SpiegelmanCFOSell3,769$87.07$328,166.83View SEC Filing  
5/18/2016Robert BaffiEVPSell5,000$87.05$435,250.00View SEC Filing  
5/10/2016George Eric DavisEVPSell14,658$85.11$1,247,542.38View SEC Filing  
5/5/2016Jean Jacques BienaimeCEOSell50,000$80.15$4,007,500.00View SEC Filing  
5/3/2016Jeffrey Robert AjerEVPSell415$86.03$35,702.45View SEC Filing  
5/2/2016Jean Jacques BienaimeCEOSell36,500$85.01$3,102,865.00View SEC Filing  
3/14/2016George Eric DavisEVPSell1,996$86.21$172,075.16View SEC Filing  
3/4/2016Jeffrey Robert AjerSVPSell1,255$88.42$110,967.10View SEC Filing  
3/2/2016Daniel K SpiegelmanCFOSell4,623$86.12$398,132.76View SEC Filing  
3/1/2016Jean Jacques BienaimeCEOSell10,000$84.28$842,800.00View SEC Filing  
2/22/2016Michael G GreyDirectorSell7,500$80.00$600,000.00View SEC Filing  
12/16/2015George Eric DavisSVPSell1,362$100.00$136,200.00View SEC Filing  
11/30/2015Jean Jacques BienaimeCEOSell1,000$94.74$94,740.00View SEC Filing  
11/16/2015Daniel K. SpiegelmanCFOSell20,000$104.30$2,086,000.00View SEC Filing  
11/16/2015V Bryan LawlisDirectorSell8,550$106.90$913,995.00View SEC Filing  
10/15/2015Jean Jacques BienaimeCEOSell1,000$108.24$108,240.00View SEC Filing  
9/14/2015Jean Jacques BienaimeCEOSell1,000$131.43$131,430.00View SEC Filing  
7/20/2015Jeffrey Robert AjerSVPSell3,000$150.00$450,000.00View SEC Filing  
7/7/2015Jean Jacques BienaimeCEOSell1,500$139.07$208,605.00View SEC Filing  
6/5/2015Daniel K SpiegelmanCFOSell1,649$122.30$201,672.70View SEC Filing  
6/5/2015Henry J FuchsEVPSell1,864$122.32$228,004.48View SEC Filing  
6/4/2015Jeffrey Robert AjerSVPSell1,362$122.35$166,640.70View SEC Filing  
6/1/2015Daniel K SpiegelmanCFOSell5,523$124.73$688,883.79View SEC Filing  
6/1/2015Jeffrey Robert AjerSVPSell377$123.76$46,657.52View SEC Filing  
5/29/2015Daniel K SpiegelmanCFOSell1,578$126.15$199,064.70View SEC Filing  
5/26/2015Jeffrey Robert AjerSVPSell1,625$126.55$205,643.75View SEC Filing  
5/18/2015Daniel K SpiegelmanCFOSell2,059$124.77$256,901.43View SEC Filing  
5/18/2015George Eric DavisSVPSell2,558$125.26$320,415.08View SEC Filing  
5/18/2015Henry J FuchsEVPSell1,864$124.78$232,589.92View SEC Filing  
5/13/2015Henry J FuchsEVPSell1,434$121.37$174,044.58View SEC Filing  
5/11/2015Henry J FuchsEVPSell2,869$121.64$348,985.16View SEC Filing  
3/17/2015Jean Jacques BienaimeCEOSell2,000$124.17$248,340.00View SEC Filing  
3/16/2015Henry J FuchsEVPSell41,315$123.57$5,105,294.55View SEC Filing  
3/16/2015Jean Jacques BienaimeCEOSell1,000$123.48$123,480.00View SEC Filing  
3/10/2015Jean Jacques BienaimeCEOSell21,021$112.39$2,362,550.19View SEC Filing  
3/9/2015Jean Jacques BienaimeCEOSell19,000$112.13$2,130,470.00View SEC Filing  
3/5/2015Jean Jacques BienaimeCEOSell10,000$113.70$1,137,000.00View SEC Filing  
3/5/2015Robert BaffiEVPSell14,051$116.37$1,635,114.87View SEC Filing  
3/4/2015Jean Jacques BienaimeCEOSell13,916$107.92$1,501,814.72View SEC Filing  
3/3/2015Jean Jacques BienaimeCEOSell5,000$107.42$537,100.00View SEC Filing  
3/2/2015Daniel K SpiegelmanCFOSell15,500$107.00$1,658,500.00View SEC Filing  
3/2/2015George Eric DavisSVPSell23,000$108.31$2,491,130.00View SEC Filing  
3/2/2015Jean Jacques BienaimeCEOSell5,000$108.44$542,200.00View SEC Filing  
1/9/2015Jean Jacques BienaimeCEOSell2,000$94.14$188,280.00View SEC Filing  
12/24/2014Jean Jacques BienaimeCEOSell5,000$88.73$443,650.00View SEC Filing  
12/10/2014Jean Jacques BienaimeCEOSell2,000$95.00$190,000.00View SEC Filing  
12/4/2014Alan LewisDirectorSell7,500$89.90$674,250.00View SEC Filing  
12/2/2014Brian MuellerVPSell11,950$90.91$1,086,374.50View SEC Filing  
11/25/2014George Eric DavisSVPSell20,000$89.75$1,795,000.00View SEC Filing  
11/25/2014Jean Jacques BienaimeCEOSell2,000$90.00$180,000.00View SEC Filing  
11/12/2014Jean Jacques BienaimeCEOSell1,000$81.51$81,510.00View SEC Filing  
11/10/2014Henry J FuchsEVPSell20,000$86.55$1,731,000.00View SEC Filing  
11/10/2014Jean Jacques BienaimeCEOSell4,000$87.00$348,000.00View SEC Filing  
11/3/2014Jean Jacques BienaimeCEOSell3,000$85.33$255,990.00View SEC Filing  
11/3/2014Jeffrey Robert AjerSVPSell47$83.54$3,926.38View SEC Filing  
10/30/2014Robert BaffiEVPSell75,425$81.34$6,135,069.50View SEC Filing  
10/24/2014Jean Jacques BienaimeCEOSell2,000$80.00$160,000.00View SEC Filing  
9/19/2014George Eric DavisSVPSell17,536$69.75$1,223,136.00View SEC Filing  
9/2/2014Daniel K SpiegelmanCFOSell16,000$69.83$1,117,280.00View SEC Filing  
8/20/2014Jean Jacques BienaimeCEOSell5,000$70.00$350,000.00View SEC Filing  
8/5/2014Henry J FuchsEVPSell10,000$65.00$650,000.00View SEC Filing  
8/1/2014Daniel K SpiegelmanCFOSell2,229$61.76$137,663.04View SEC Filing  
7/2/2014Daniel K SpiegelmanCFOSell2,229$64.00$142,656.00View SEC Filing  
6/4/2014Jean Jacques BienaimeCEOSell2,000$61.20$122,400.00View SEC Filing  
5/22/2014Jean Jacques BienaimeCEOSell1,000$56.88$56,880.00View SEC Filing  
5/21/2014Jean Jacques BienaimeCEOSell1,545$56.19$86,813.55View SEC Filing  
5/16/2014Henry FuchsEVPSell1,864$56.86$105,987.04View SEC Filing  
5/16/2014Jeffrey Robert AjerSVPSell1,004$56.91$57,137.64View SEC Filing  
5/16/2014V Bryan LawlisDirectorSell1,700$56.87$96,679.00View SEC Filing  
5/13/2014Henry FuchsEVPSell1,434$58.23$83,501.82View SEC Filing  
5/9/2014Henry FuchsEVPSell3,479$57.91$201,468.89View SEC Filing  
2/3/2014Henry FuchsEVPSell10,000$67.70$677,000.00View SEC Filing  
12/24/2013Jean Jacques BienaimeCEOSell10,000$68.71$687,100.00View SEC Filing  
12/5/2013Jean Jacques BienaimeCEOSell5,000$69.70$348,500.00View SEC Filing  
10/16/2013Jean Jacques BienaimeCEOSell2,000$67.73$135,460.00View SEC Filing  
10/10/2013Jean Jacques BienaimeCEOSell3,000$66.76$200,280.00View SEC Filing  
9/19/2013Henry FuchsEVPSell10,000$80.19$801,900.00View SEC Filing  
9/16/2013Jean Jacques BienaimeCEOSell2,000$73.08$146,160.00View SEC Filing  
9/9/2013Robert BaffiEVPSell20,000$73.00$1,460,000.00View SEC Filing  
9/5/2013Henry J FuchsEVPSell10,000$70.00$700,000.00View SEC Filing  
9/4/2013Daniel K SpiegelmanCFOSell9,000$69.00$621,000.00View SEC Filing  
8/15/2013Jean Jacques BienaimeCEOSell1,000$64.36$64,360.00View SEC Filing  
7/1/2013Daniel K SpiegelmanCFOSell4,066$59.78$243,065.48View SEC Filing  
7/1/2013Henry J FuchsEVPSell10,000$60.00$600,000.00View SEC Filing  
6/3/2013Henry J FuchsEVPSell1,098$58.32$64,035.36View SEC Filing  
5/23/2013Henry J FuchsEVPSell20,609$66.29$1,366,170.61View SEC Filing  
5/22/2013Mark WoodVPSell3,103$67.12$208,273.36View SEC Filing  
5/21/2013Jean Jacques BienaimeCEOSell2,000$64.14$128,280.00View SEC Filing  
5/16/2013Jean Jacques BienaimeCEOSell12,000$67.90$814,800.00View SEC Filing  
5/14/2013Brian MuellerVPSell4,947$70.35$348,021.45View SEC Filing  
5/14/2013George Eric DavisSVPSell20,000$70.34$1,406,800.00View SEC Filing  
5/14/2013Jean Jacques BienaimeCEOSell15,000$70.17$1,052,550.00View SEC Filing  
5/13/2013Jean Jacques BienaimeCEOSell15,800$68.77$1,086,566.00View SEC Filing  
5/13/2013Jeffrey Robert AjerSVPSell1,248$69.26$86,436.48View SEC Filing  
5/8/2013Jean Jacques BienaimeCEOSell4,000$65.87$263,480.00View SEC Filing  
5/2/2013Jean Jacques BienaimeCEOSell3,000$64.99$194,970.00View SEC Filing  
4/10/2013Robert BaffiEVPSell20,000$64.00$1,280,000.00View SEC Filing  
3/22/2013Mark WoodVPSell3,103$60.21$186,831.63View SEC Filing  
3/4/2013George Eric DavisSVPSell4,000$60.18$240,720.00View SEC Filing  
2/22/2013Mark WoodVPSell3,103$55.22$171,347.66View SEC Filing  
2/4/2013Jean Jacques BienaimeCEOSell2,000$55.77$111,540.00View SEC Filing  
12/27/2012Jean Jacques BienaimeCEOSell17,000$48.37$822,290.00View SEC Filing  
11/12/2012George Eric DavisSVPSell99,075$48.45$4,800,183.75View SEC Filing  
9/4/2012Henry J FuchsEVPSell5,000$37.76$188,800.00View SEC Filing  
8/22/2012Mark WoodVPSell2,665$37.93$101,083.45View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for BioMarin Pharmaceutical (NASDAQ:BMRN)
Latest Headlines for BioMarin Pharmaceutical (NASDAQ:BMRN)
Source:
DateHeadline
americanbankingnews.com logoBioMarin Pharmaceutical Inc. (BMRN) Price Target Raised to $124.00 at Credit Suisse Group
www.americanbankingnews.com - October 19 at 11:44 AM
americanbankingnews.com logoBioMarin Pharmaceutical Inc. (BMRN) Rating Reiterated by Leerink Swann
www.americanbankingnews.com - October 19 at 11:44 AM
americanbankingnews.com logoBioMarin Pharmaceutical Inc. (BMRN) to Release Earnings on Thursday
www.americanbankingnews.com - October 19 at 2:32 AM
nasdaq.com logoMarket Close Report: Historical high reached as NASDAQ Composite Index closes at 6624.22. - Nasdaq
www.nasdaq.com - October 18 at 10:58 PM
streetinsider.com logoBioMarin Pharma (BMRN) Provides Highlights from R&D Day, Reaffirms Guidance - StreetInsider.com
www.streetinsider.com - October 18 at 10:58 PM
finance.yahoo.com logoBioMarin is 'close as can get' to a hemophilia cure, CEO ...
finance.yahoo.com - October 18 at 10:58 PM
finance.yahoo.com logoBioMarin Pharmaceutical: Cramer's Top Takeaways
finance.yahoo.com - October 18 at 10:58 PM
streetinsider.com logoBioMarin Pharma (BMRN) Provides Highlights from R&D Day, Reaffirms Guidance
www.streetinsider.com - October 18 at 5:56 PM
americanbankingnews.com logoZacks: Brokerages Anticipate BioMarin Pharmaceutical Inc. (BMRN) Will Announce Earnings of -$0.09 Per Share
www.americanbankingnews.com - October 18 at 6:34 AM
americanbankingnews.com logoComparing BioMarin Pharmaceutical (BMRN) & Its Competitors
www.americanbankingnews.com - October 17 at 12:28 AM
americanbankingnews.com logoHead to Head Comparison: BioMarin Pharmaceutical (BMRN) & Its Rivals
www.americanbankingnews.com - October 17 at 12:28 AM
globenewswire.com logoBioMarin Pharmaceutical, Inc. (Nasdaq: BMRN) to Ring The Nasdaq Stock Market Closing Bell - GlobeNewswire (press release)
globenewswire.com - October 16 at 5:25 PM
feeds.benzinga.com logoBioMarin Pharmaceutical, Inc. (Nasdaq: BMRN) to Ring The Nasdaq Stock Market Closing Bell
feeds.benzinga.com - October 16 at 2:49 PM
marketwatch.com logoSpark Therapeutics' promising gene therapy for vision loss could cost $1 million - MarketWatch
www.marketwatch.com - October 13 at 5:17 PM
finance.yahoo.com logoHow Spark's Gene Therapy Win Could Also Be A Boon For These Biotechs
finance.yahoo.com - October 13 at 5:17 PM
americanbankingnews.com logoBioMarin Pharmaceutical Inc. (BMRN) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 12 at 6:10 PM
finance.yahoo.com logoBioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York
finance.yahoo.com - October 11 at 6:07 PM
finance.yahoo.com logoBioMarin to Host Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday, October 26 at 4:30 p.m. ET
finance.yahoo.com - October 10 at 5:54 PM
americanbankingnews.com logoBioMarin Pharmaceutical's (BMRN) "Overweight" Rating Reaffirmed at Morgan Stanley
www.americanbankingnews.com - October 7 at 1:04 PM
americanbankingnews.com logoBioMarin Pharmaceutical Inc. (BMRN) Earns "Buy" Rating from Goldman Sachs Group, Inc. (The)
www.americanbankingnews.com - October 7 at 12:58 AM
streetinsider.com logoBioMarin Pharmaceutical Inc.
www.streetinsider.com - October 5 at 8:12 AM
prnewswire.com logoBioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors - PR Newswire (press release)
www.prnewswire.com - October 3 at 4:27 PM
finance.yahoo.com logoBioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors
finance.yahoo.com - October 3 at 9:54 AM
americanbankingnews.com logoInsider Selling: BioMarin Pharmaceutical Inc. (BMRN) EVP Sells $1,702,098.45 in Stock
www.americanbankingnews.com - October 2 at 10:28 PM
nasdaq.com logoInteresting BMRN Put And Call Options For December 15th
www.nasdaq.com - October 2 at 1:24 PM
americanbankingnews.com logoKamada (KMDA) and BioMarin Pharmaceutical (BMRN) Head-To-Head Comparison
www.americanbankingnews.com - September 30 at 2:30 AM
americanbankingnews.com logo Brokerages Anticipate BioMarin Pharmaceutical Inc. (BMRN) to Announce -$0.09 Earnings Per Share
www.americanbankingnews.com - September 29 at 10:40 AM
investopedia.com logo8 Stocks for the Next Gene Revolution
www.investopedia.com - September 29 at 8:48 AM
americanbankingnews.com logoBioMarin Pharmaceutical (BMRN) and Vitae Pharmaceuticals (VTAE) Critical Contrast
www.americanbankingnews.com - September 28 at 8:50 PM
seekingalpha.com logoSarepta: Uncertainties And Controversies Surround Its Trials
seekingalpha.com - September 28 at 10:44 AM
americanbankingnews.com logoBioMarin Pharmaceutical Inc. (BMRN) EVP Sells $334,495.00 in Stock
www.americanbankingnews.com - September 26 at 10:33 PM
finance.yahoo.com logoHere's Why Sarepta Stock is Up More Than 60% So Far in 2017
finance.yahoo.com - September 25 at 8:06 PM
americanbankingnews.com logoBioMarin Pharmaceutical Inc. (BMRN) Rating Reiterated by Piper Jaffray Companies
www.americanbankingnews.com - September 21 at 5:02 PM
americanbankingnews.com logoBioMarin Pharmaceutical Inc. (BMRN) Insider Sells $1,357,500.00 in Stock
www.americanbankingnews.com - September 19 at 4:28 PM
americanbankingnews.com logoV Bryan Lawlis Sells 3,750 Shares of BioMarin Pharmaceutical Inc. (BMRN) Stock
www.americanbankingnews.com - September 19 at 4:24 PM
zacks.com logoBioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA
www.zacks.com - September 18 at 5:00 PM
americanbankingnews.com logoBioMarin Pharmaceutical Inc. (BMRN) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 17 at 2:48 PM
streetinsider.com logoBioMarin Pharma (BMRN) Says FDA Isn't Planning Advisory Committee Meeting for Pegvaliase BLA
www.streetinsider.com - September 15 at 5:02 PM
americanbankingnews.com logoBioMarin Pharmaceutical Inc. (BMRN) Stock Rating Reaffirmed by BMO Capital Markets
www.americanbankingnews.com - September 15 at 4:22 PM
americanbankingnews.com logoBioMarin Pharmaceutical Inc. (BMRN) Earns Sector Perform Rating from Analysts at Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 10:36 PM
streetinsider.com logoBioMarin Pharma (BMRN) Says FDA Isn't Planning Advisory Committee Meeting for Pegvaliase BLA - StreetInsider.com
www.streetinsider.com - September 14 at 10:20 PM
seekingalpha.com logoNo Ad Com planned for BioMarin's pegvaliase - Seeking Alpha
seekingalpha.com - September 14 at 5:18 PM
finance.yahoo.com logoFDA Not Currently Planning to Hold Advisory Committee Meeting for BioMarin's Pegvaliase Biologics License Application (BLA)
finance.yahoo.com - September 14 at 5:18 PM
americanbankingnews.com logoBioMarin Pharmaceutical Inc. (BMRN) Given Overweight Rating at Piper Jaffray Companies
www.americanbankingnews.com - September 14 at 9:08 AM
streetinsider.com logoUPDATE: Piper Jaffray Assumes BioMarin Pharmaceutical Inc. (BMRN) at Overweight - StreetInsider.com
www.streetinsider.com - September 13 at 10:50 PM
finance.yahoo.com logoETFs with exposure to BioMarin Pharmaceutical, Inc. : September 13, 2017
finance.yahoo.com - September 13 at 5:48 PM
finance.yahoo.com logoBioMarin’s Strong Pipeline Could Be a Long-Term Growth Driver
finance.yahoo.com - September 12 at 5:02 PM
americanbankingnews.com logo$359.45 Million in Sales Expected for BioMarin Pharmaceutical Inc. (BMRN) This Quarter
www.americanbankingnews.com - September 12 at 11:18 AM
finance.yahoo.com logoHow Did BioMarin Pharmaceuticals’ Drugs Perform in 1H17?
finance.yahoo.com - September 11 at 5:17 PM
finance.yahoo.com logoBioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017
finance.yahoo.com - September 11 at 5:17 PM

Social

Chart

BioMarin Pharmaceutical (BMRN) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.